RMC-9805 + 5-fluorouracil

RMC-9805 + 5-fluorouracil is an investigational combination therapy composed of two agents: RMC-9805, a covalent small molecule inhibitor specifically targeting the KRAS G12D mutant oncoprotein in cancer, and 5-fluorouracil (5-FU), a well-established antimetabolite chemotherapy drug. RMC-9805 binds selectively to the active (ON) state of KRAS G12D, blocking downstream signaling and inducing tumor regression by promoting apoptosis in KRAS G12D-mutant cancer cells. 5-FU inhibits thymidylate synthase, disrupting DNA synthesis and repair, and also induces cell death by interfering with RNA synthesis. The combination is designed for the treatment of cancers harboring KRAS G12D mutations, such as gastrointestinal tumors and pancreatic adenocarcinoma. Clinical evaluation is ongoing, with the combination being tested for enhanced efficacy in solid tumors with these mutations[1][3][5][7].

Other names

fluorouracil